Navigation Links
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Date:3/3/2008

Progress validates HUYA's innovative U.S./China pharmaceutical

co-development model

SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

According to Mireille Gingras, Ph.D., CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of ou
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
2. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... R.I., Oct. 15 CVS/pharmacy announced today that its ... in light of manufacturer delays in delivery of seasonal ... MinuteClinic will continue to administer seasonal flu vaccines at ... season with the supply of vaccine replenished as frequently ...
... Inc. (Nasdaq: CYNO ), a leading developer ... systems, today announced that the company will host its third-quarter ... a.m. ET. , On the call, President and Chief Executive ... Officer Timothy Baker will discuss Cynosure,s financial results, as well ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... An aneurysm is an abnormal dilation of a blood vessel. ... a risk to health due to their potential to rupture, ... the abdominal and thoracic aorta, and brain. Potential blood vessel ... but only if they are above a certain diameter.// Some ...
... by periodontal disease, could carry increased risk of ... suggested that bacteria responsible for oral infections could ... C-reactive protein and other inflammatory agents associated with ... two has not been established. ,A research ...
... is underdiagnosed and treated in many cases, say US doctors. ... and arms become blocked with the same kind of fatty ... best way of treating it is very simple - keep ... actually increase the ability to walk with ease. Positive effects ...
... Bubonic plague, the bacterium blamed for the Black Death ... biological weapon, has had its entire genome sequenced. The ... and picking up new genes from other microbes. ,That ... emerge. More ominously, it suggests that enhanced strains might ...
... research confirms that the main ingredient in the -- depo ... when used long term. The younger you are when you ... problems later in life. // ,From ... bone mass is constantly breaking down and re-building, usually in ...
... be prevented if all pregnant women stopped smoking, say Australian ... training in helping women quit.,They found that smoking doubles the ... or a pre-term birth, and triples the rate of SIDS ... entirely, they need to cut their smoking by half to ...
Cached Medicine News:Health News:Sequencing of the Plague 2
... and 4 metal chest electrodes on ... procedure enabling a patient to easily ... ECG through a simple change of ... per lead and 10 seconds of ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
... The Digital-Photo Adapter ... designed optics for the ... technology. In combination with ... this is the best ...
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
Medicine Products: